Immunitybio Inc. (IBRX)

$5.24

+0.32

(+6.5%)

Market is closed - opens 7 PM, 18 Apr 2024

Insights on Immunitybio Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 41.0K → 139.0K (in $), with an average increase of 45.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -95.58M → -233.39M (in $), with an average decrease of 144.2% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 315.0%

Performance

  • $4.77
    $5.42
    $5.24
    downward going graph

    8.97%

    Downside

    Day's Volatility :11.99%

    Upside

    3.32%

    downward going graph
  • $1.25
    $6.93
    $5.24
    downward going graph

    76.15%

    Downside

    52 Weeks Volatility :81.96%

    Upside

    24.39%

    downward going graph

Returns

PeriodImmunitybio Inc.Sector (Health Care)Index (Russel 2000)
3 Months
44.35%
-0.7%
0.0%
6 Months
271.63%
6.6%
0.0%
1 Year
144.86%
3.7%
-1.5%
3 Years
-69.1%
14.0%
-21.8%

Highlights

Market Capitalization
3.3B
Book Value
- $0.87
Earnings Per Share (EPS)
-1.15
Wall Street Target Price
5.0
Profit Margin
0.0%
Operating Margin TTM
-60792.8%
Return On Assets TTM
-52.11%
Return On Equity TTM
0.0%
Revenue TTM
622.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
90.4%
Gross Profit TTM
240.0K
EBITDA
-342.9M
Diluted Eps TTM
-1.15
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.68
EPS Estimate Next Year
-0.45
EPS Estimate Current Quarter
-0.18
EPS Estimate Next Quarter
-0.16

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Immunitybio Inc.(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 4.58%

Current $5.24
Target $5.00

Company Financials

FY18Y/Y Change
Revenue
47.0K
↑ 4.44%
Net Income
-96.2M
↓ 0.2%
Net Profit Margin
-204.7K%
↑ 9537.16%
FY19Y/Y Change
Revenue
2.2M
↑ 4585.11%
Net Income
-160.2M
↑ 66.44%
Net Profit Margin
-7.3K%
↑ 197462.87%
FY20Y/Y Change
Revenue
605.0K
↓ 72.52%
Net Income
-224.2M
↑ 39.98%
Net Profit Margin
-37.1K%
↓ 29782.4%
FY21Y/Y Change
Revenue
934.0K
↑ 54.38%
Net Income
-349.8M
↑ 56.05%
Net Profit Margin
-37.5K%
↓ 401.26%
FY22Y/Y Change
Revenue
240.0K
↓ 74.3%
Net Income
-417.3M
↑ 19.29%
Net Profit Margin
-173.9K%
↓ 136426.37%
FY23Y/Y Change
Revenue
622.0K
↑ 159.17%
Net Income
-583.2M
↑ 39.75%
Net Profit Margin
-93.8K%
↑ 80121.92%
Q3 FY22Q/Q Change
Revenue
118.0K
↑ 237.14%
Net Income
-110.9M
↑ 17.29%
Net Profit Margin
-94.0K%
↑ 176236.18%
Q4 FY22Q/Q Change
Revenue
73.0K
↓ 38.14%
Net Income
-108.3M
↓ 2.35%
Net Profit Margin
-148.4K%
↓ 54376.53%
Q1 FY23Q/Q Change
Revenue
360.0K
↑ 393.15%
Net Income
-151.2M
↑ 39.54%
Net Profit Margin
-42.0K%
↑ 106402.34%
Q2 FY23Q/Q Change
Revenue
41.0K
↓ 88.61%
Net Income
-137.9M
↓ 8.79%
Net Profit Margin
-336.3K%
↓ 294300.8%
Q3 FY23Q/Q Change
Revenue
82.0K
↑ 100.0%
Net Income
-95.6M
↓ 30.68%
Net Profit Margin
-116.6K%
↑ 219726.83%
Q4 FY23Q/Q Change
Revenue
139.0K
↑ 69.51%
Net Income
-233.4M
↑ 144.18%
Net Profit Margin
-167.9K%
↓ 51344.5%
FY18Y/Y Change
Total Assets
182.0M
↓ 27.35%
Total Liabilities
35.9M
↑ 13.76%
FY19Y/Y Change
Total Assets
143.1M
↓ 21.34%
Total Liabilities
22.4M
↓ 37.56%
FY20Y/Y Change
Total Assets
221.4M
↑ 54.68%
Total Liabilities
339.9M
↑ 1414.31%
FY21Y/Y Change
Total Assets
468.9M
↑ 111.81%
Total Liabilities
712.8M
↑ 109.73%
FY22Y/Y Change
Total Assets
362.4M
↓ 22.72%
Total Liabilities
812.2M
↑ 13.94%
FY23Y/Y Change
Total Assets
504.5M
↑ 39.21%
Total Liabilities
1.1B
↑ 34.26%
Q3 FY22Q/Q Change
Total Assets
352.9M
↑ 11.09%
Total Liabilities
782.0M
↑ 5.72%
Q4 FY22Q/Q Change
Total Assets
362.4M
↑ 2.67%
Total Liabilities
812.2M
↑ 3.86%
Q1 FY23Q/Q Change
Total Assets
343.4M
↓ 5.23%
Total Liabilities
875.1M
↑ 7.75%
Q2 FY23Q/Q Change
Total Assets
291.2M
↓ 15.19%
Total Liabilities
936.4M
↑ 7.0%
Q3 FY23Q/Q Change
Total Assets
432.4M
↑ 48.48%
Total Liabilities
843.1M
↓ 9.97%
Q4 FY23Q/Q Change
Total Assets
504.5M
↑ 16.66%
Total Liabilities
1.1B
↑ 29.34%
FY18Y/Y Change
Operating Cash Flow
-63.4M
↑ 29.93%
Investing Cash Flow
25.7M
↓ 74.2%
Financing Cash Flow
-771.0K
↓ 97.8%
FY19Y/Y Change
Operating Cash Flow
-152.1M
↑ 139.99%
Investing Cash Flow
-6.3M
↓ 124.59%
Financing Cash Flow
114.3M
↓ 14922.18%
FY20Y/Y Change
Operating Cash Flow
-171.7M
↑ 12.9%
Investing Cash Flow
-1.4M
↓ 78.29%
Financing Cash Flow
150.7M
↑ 31.85%
FY21Y/Y Change
Operating Cash Flow
-274.4M
↑ 59.8%
Investing Cash Flow
-84.9M
↑ 6091.54%
Financing Cash Flow
505.4M
↑ 235.45%
FY22Y/Y Change
Operating Cash Flow
-337.5M
↑ 22.99%
Investing Cash Flow
27.3M
↓ 132.16%
Financing Cash Flow
233.6M
↓ 53.78%
Q3 FY22Q/Q Change
Operating Cash Flow
-80.6M
↓ 11.67%
Investing Cash Flow
-1.2M
↓ 101.0%
Financing Cash Flow
124.0M
↓ 826673.33%
Q4 FY22Q/Q Change
Operating Cash Flow
-90.7M
↑ 12.56%
Investing Cash Flow
-18.9M
↑ 1517.64%
Financing Cash Flow
109.9M
↓ 11.33%
Q1 FY23Q/Q Change
Operating Cash Flow
-84.3M
↓ 7.07%
Investing Cash Flow
-8.5M
↓ 55.1%
Financing Cash Flow
76.9M
↓ 30.06%
Q2 FY23Q/Q Change
Operating Cash Flow
-79.8M
↓ 5.38%
Investing Cash Flow
-8.6M
↑ 1.41%
Financing Cash Flow
43.4M
↓ 43.54%

Technicals Summary

Sell

Neutral

Buy

Immunitybio Inc. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Immunitybio Inc.
Immunitybio Inc.
0.19%
271.63%
144.86%
-69.1%
-83.87%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Immunitybio Inc.
Immunitybio Inc.
NA
NA
NA
-0.68
0.0
-0.52
NA
-0.87
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Immunitybio Inc.
Immunitybio Inc.
Buy
$3.3B
-83.87%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • Vanguard Group Inc

    1.98%
  • BlackRock Inc

    1.59%
  • State Street Corporation

    1.41%
  • Geode Capital Management, LLC

    0.50%
  • Goldman Sachs Group Inc

    0.38%
  • Credit Suisse First Boston (CSFB)

    0.23%

Corporate Announcements

  • Immunitybio Inc. Earnings

    Immunitybio Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer (‘nk’) and t cells, tumoricidal macrophages, and memory t cells.

Organization
Immunitybio Inc.
Employees
628
CEO
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc.
Industry
Healthcare

FAQs